Biogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug Struggles - The Wall Street Journal

Michel Vounatsos’s resignation comes as the company attempts to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.

Biogen Inc. is shedding Chief Executive Michel Vounatsos and effectively abandoning its high-profile Alzheimers disease treatment Aduhelm as it attempts to chart a new course after Medicares devastat… [+266 chars]

full article...